Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01167972

Acronym

MUTACT

Enrollment

2000

Registered

2010-07-22

Start date

2010-09-30

Completion date

2012-09-30

Last updated

2012-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Keywords

M + mutation, Non Small Cell Lung Cancer adenocarcinoma, To determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

Brief summary

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.

Detailed description

MSD

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma) * Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

Exclusion criteria

* Assessment of mutational status of EGFR is not done

Design outcomes

Primary

Measure	Time frame
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma	At baseline

Secondary

Measure	Time frame
Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).	12 months / At each visit
Describe the therapeutic management of patients with EGFR M +.	12 months / At each visit
Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012	12 months / At each visit

Countries

France

Outcome results